GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Revenue

Taisho Pharmaceutical Holdings Co (TSE:4581) Revenue : 円320,385 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Revenue?

Taisho Pharmaceutical Holdings Co's revenue for the three months ended in Dec. 2023 was 円83,576 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was 円320,385 Mil. Taisho Pharmaceutical Holdings Co's Revenue per Share for the three months ended in Dec. 2023 was 円1,017.92. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was 円3,902.86.

During the past 12 months, the average Revenue per Share Growth Rate of Taisho Pharmaceutical Holdings Co was 8.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 0.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 0.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Taisho Pharmaceutical Holdings Co's highest 3-Year average Revenue per Share Growth Rate was 5.40% per year. The lowest was -3.00% per year. And the median was 0.60% per year.


Taisho Pharmaceutical Holdings Co Revenue Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Revenue Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 261,369.00 288,720.00 282,037.00 268,203.00 301,381.00

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83,151.00 73,712.00 80,802.00 82,295.00 83,576.00

Competitive Comparison of Taisho Pharmaceutical Holdings Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's Revenue distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's Revenue falls into.



Taisho Pharmaceutical Holdings Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円320,385 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taisho Pharmaceutical Holdings Co  (TSE:4581) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Taisho Pharmaceutical Holdings Co Revenue Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines